AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

PMCF Study on the Safety, Performance and Clinical Benefits Data of the Anatomical Shoulder 2.0 Fracture System

Recruitingn/aAges 18 Years - anyAllZimmer Biomet
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The study is a multicenter, retrospective and prospective, non-randomized, non-controlled and consecutive series post-market study. The purpose of this study is to collect long-term data confirming safety, performance and clinical benefits of the Anatomical Shoulder 2.0 Fracture System (Implants and Instrumentation) when used for fracture shoulder arthroplasty. The primary objective is the assessment of safety by analyzing implant survivorship. This will be established by recording the incidence and frequency of revisions, complications and adverse events. Relation of the events to implant, instrumentation and/or procedure should be specified. The secondary objective is the assessment of performance and clinical benefits by recording patient-reported clinical outcome measures (PROMs) as well as radiographic outcomes.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Patients 18 years or older and skeletally mature * Patients capable of understanding the surgeon's explanations and following his instructions, able and willing to participate in the follow-up program and who gave consent to take part in the study * Replacement of the proximal humerus and the glenoid articular surface of the scapula during total-, hemi- and fracture shoulder arthroplasty in treatment of the following: 1. Complex 3- and 4- part fractures of the proximal humerus with subluxation of the head fragment 2. Complex 3- and 4- part fractures of the proximal humerus with loosening of the spongiosa in the head fragment 3. Complex 3- and 4- part fractures of the proximal humerus with additional cross split of the head fragment 4. Fracture instability after osteosynthesis of 3- and 4-part fracture fragments of the proximal humerus 5. Posttraumatic necrosis of the humeral head 6. Posttraumatic arthrosis after humeral head fracture Exclusion Criteria: * Patients who are unwilling or unable to give consent, not willing to return for study required follow-up visits and/or to comply with the follow-up program. * The patient is known to be pregnant or breastfeeding * Patients who have any condition that would in the judgment of the Investigator place the patient at undue risk or interfere with the study. * Patient is a vulnerable subject (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, anticipated to be non-compliant). * Patients with plans to relocate during the study follow-up period * Signs of infection * Extensive stiffening of the shoulder joint without pain
๐Ÿ’Š

What it tests

  • Not listed
๐Ÿ“

Where

1 site
Salamenca University Hospital
Salamanca, Spain
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy